Stay Safe. Stay Healthy.
14 June 2021
GST Council recommends a reduction in GST rates on essential goods being used for COVID-19 relief and management

In the 43rd GST Council meeting held on 28 May 2021, the Council had decided to constitute a Group of Ministers (GoM) to delve into the need to provide further tax relief by reducing GST rates on essential items used for COVID-19 relief. The GoM headed by Meghalaya Chief Minister Conrad Sangma had submitted their report on 7 June 2021 to the GST Council. The recommendations fell more or less in line with the earlier suggestions of the fitment committee to the GST council.

Based on the report submitted by the GoM, the 44th GST Council meeting has recommended reducing the GST rates on specified items being used in COVID-19 relief and management till 30 September 2021.

Category I: Medicines

 
Sr. No. Description Present GST Rate Proposed GST Rate
1 Tocilizumab 5% Nil
2 Amphotericin B 5% Nil
3 Anti-Coagulants like Heparin 12% 5%
4 Remdesivir 12% 5%
5 Any other drug recommended by the Ministry of Health and Family Welfare (MoHFW) and Department of Pharma (DoP) for COVID-19 treatment Applicable Rate 5%


Category II: Oxygen, Oxygen generation equipment and related medical devices
 
Sr. No. Description Present GST Rate Proposed GST Rate
1 Medical Grade Oxygen 12% 5%
2 Oxygen Concentrator/Generator, including personal imports thereof 12% 5%
3 Ventilators 12% 5%
4 Ventilator masks /canula/helmet 12% 5%
5 BiPAP Machine 12% 5%
6 High flow nasal canula (HFNC) device 12% 5%


Category III : Testing kits and machines
 
Sr. No. Description Present GST Rate Proposed GST Rate
1 COVID-19 Testing Kits 12% 5%
2 Specified Inflammatory Diagnostic Kits, namely DDimer,IL-6, Ferritin and LDH 12% 5%


Category IV : Other COVID-19 related relief material
 
Sr. No. Description Present GST Rate Proposed GST Rate
1 Pulse Oximeters, including personal imports thereof 12% 5%
2 Hand Sanitizer 18% 5%
3 Temperature check equipment 18% 5%
4 Gas/Electric/other furnaces for crematorium, including their installation, etc. 18% 5%
1 Ambulances 28% 12%
 
 
Our Comments

Earlier it was suggested that the Union Finance Ministry was not in favor of granting complete GST exemptions on essential medical goods as it could lead to additional tax costs in the supply chain due to blockage/reversal of input tax credit. In line with this, the GST Council has exempted only a few of the essential drugs from GST. In most cases, the GST Council has adopted an approach of reducing GST rates rather than a complete exemption to avoid blockage of GST credit.

It is expected that these rate reductions on key medical items such as Amphotericin B, Remdesivir, Medical grade oxygen, etc., will boost the nations' fight against COVID-19 by making these items available at affordable prices.

The Council could have also explored the possibility of granting a refund to the final supplier in the supply chain discharging GST but not collecting from the buyer. This may not be a simple possibility under the present framework of the GST law. Hence, a refund may have to be granted outside of GST law subject to non-collection of tax from ultimate customers. This could have helped avoid any disruptions in credit flow and also ensure that passing of GST cost on end consumers is viably avoided.

Furthermore, now that vaccination drives organized by various public/private sector organizations to their employees are thriving, clarity on levy of GST on doses administered to employees/their dependants, ITC claim, GST applicability for arranging the administering of vaccines, etc. would have been highly appreciated by the industry.
Nexdigm (SKP)
Urmi Axis | 7th Floor | Famous Studio Lane |
Mahalaxmi | Mumbai | 400 011 | India
+91 22 6730 9000 | ThinkNext@nexdigm.com | www.nexdigm.com
USA | Canada | India | UAE | Japan | Hong Kong
DISCLAIMER
This alert contains general information which is provided on an “as is” basis without warranties of any kind, express or implied and is not intended to address any particular situation. The information contained herein may not be comprehensive and should not be construed as specific advice or opinion. This alert should not be substituted for any professional advice or service, and it should not be acted or relied upon or used as a basis for any decision or action that may affect you or your business. It is also expressly clarified that this alert is not intended to be a form of solicitation or invitation or advertisement to create any adviser-client relationship.

Whilst every effort has been made to ensure the accuracy of the information contained in this alert, the same cannot be guaranteed. We accept no liability or responsibility to any person for any loss or damage incurred by relying on the information contained in this alert.

© 2021 Nexdigm Private Limited. All rights reserved.